Suzhou Sanegene Bio Inc.
Clinical trials sponsored by Suzhou Sanegene Bio Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug SGB-7342 enters first human safety trial Results expected Oct 2026 (estimated)
- Can a single injection drug calm the immune attack on kidneys? Results expected Dec 2026 (estimated)
- Can a new injection tame the blood cell destruction of PNH? Results expected Aug 2027 (estimated)
-
New injection for high blood pressure enters first human safety study
Disease control CompletedThis early-phase trial tested a single dose of SGB-3908, an experimental injectable drug, in 40 healthy volunteers and people with mild high blood pressure. The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in a blood protei…
Phase 1 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can a new injection SGB-9768 pass its first safety test?
Knowledge-focused CompletedResearchers are testing an investigational drug called SGB-9768 in healthy adults aged 18 to 55. The trial gives a single injection under the skin and checks how the body handles the drug and whether it causes side effects. Participants are randomly assigned to receive either SGB…
Phase 1 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC